<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 161 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page160.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=161">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 161 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 161</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=161"><img src="../thumb/161.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>130 / 2020-04                                                        Cardio-Vascular Agents - 7.7.2
   Coron.heart dis: Adults: Init.20 mg dly.as sngl. dos. in even.  (S4) TABS. 41/7.5/0298, 36/7.5/0349, 0350, 0351  anorex., incr.appet., nightmares, dysgeus., blurr. vis., tinnit., diarrh.,
   Contraindications: Ac./chron.liv.dis., unexplain. persist.serum   710892-001: 5 mg, 30, R148,86  abdom.pain, dyspep., constip., flatul., hepatit., cholestat.jaund., incr.
   transaminas.elev., pregn. & lactat., porphyr., female pts.of child-bear.  705989-001: 10 mg, 30, R307,51  transaminas., hepat.fail., alanine aminotransferase incr., rash, Stev.-
   potent., safety & effic.in paed.pts.not est.  705988-001: 20 mg, 30, R445,11  Johns.syndr., tox. epiderm. necrolys., erythema multiforme, bullous
   Side effects: Bld.dyscras., mass gain, CNS effs., paraesthes., periph.  705990-002: 40 mg, 30, R541,00  rash., myalg., myopathy, rhabdomyolys., arthralg., back/neck/ex-
   neuropathy, GI disturbs., pancreatit., skin reacts., alopec., myalg., musc.   Dosage: Init.& contin.diet ther.bef.& dur.treatm. Indiv.ther.accord.  tremity pain, musc.spasms, joint swell., tendonopathy, musc.fatig.,
   cramps, myopathy, rhabdomyolys., hypersens. reacts. incl.lupus-like syndr.  to ther.goal & pt.respons.  gynecomast., asthen., flu syndr., fatig., flu syndr. Freq unknown: UTI,
   Special precautions: Fetotox.& teratogen.in rats, myopathy risk   Recomm.start.dos: 5 mg once dly. Dos.range 5-40 mg once dly.   thrombocytopen., lymphadenopathy, anaem., depress.,emot.lability,
   incr.with other meds.caus. myopathy e.g. fibrates/niacin & immuno-  Maj.pts.control.on 10 mg dos. If necess. make dos.adjustm.at   somnol,, amnes., revers.cognitive impairm., dizzin., fac. paralys., hy-
   suppress. theref.max.10 mg/day recomm., monit.INR.lev.& liv.funct.  2-4 wk.interv.  poaesthes., incoordinat., migraine, paraesthes., periph.neuropathy,
   when init.ther. & dur. ther.until stabil., sev.ren.insuffic., substant. al-  Prim.hypercholesterolaem.incl.heterozygous familial hyper-  syncope, taste loss & pervers., torticoll., amblyop., dry eyes, glauc.,
   coh.consumpt., liv.dis.hist., pre-disposit. to develop. ren.fail.second.to   cholesterolaem./mix. dyslipidaem./ dysbetalipoproteinaem.   eye haemorrh., refract.disord., vis.disturb., deafn., angina pect., dys-
   rhabdomyolys., incr. risk of ren.fail.if rhabdomyolysis occurs., monit.  & isol. hypertriglyceridaem: Init.dos: 5 mg once dly. Start. dos.of   rhythm., palpitats, chest pain, phlebit., postur.hypotens., vasodilat.,
   for myopathy & discont.if myopathy occurs/suspect., concom. cy-  20 mg may be consid.in sev. hypercholesterolaem. incl. heterozygous   flush., vasculit., asthma, bronchit., dyspn., rhinit., pharyngit., pneu-
   closporin/itraconazole/ketoconazole/ erythromycin/clarithromycin/  familial hypercholesterolaem.  monit., interstit.lung dis., oesophagit., gastrit., gastroenterit., mel-
   HIV-protease inhibit & nefazodone not recomm., withdr.tempor.in   Homozygous familial hypercholesterolaem: Init. recomm.  aena, colitis, N&V, tenesmus, upper and lower abdom. pain, eructat.,
   pts receiv.cyclospor.if system.azole deriv.antifung. reqd.  dos: 20 mg once dly.  dysphag., dry mouth, glossit., alopec., prurit., urticar., cheilitis, contact
   Drug interactions: Meds.inhibit.cytochrome P450 isoenzyme   Heterozygous familial hypercholesterolaem. in childr.10-17   dermatit., dry skin, ecchymos., eczema, petechiae, seborrh., angioneu-
   CYP3A4 incr.plasma lev., digoxin lev.incr., anticoag.eff.of coumar.  yrs: Usual dos.range: 5-20 mg once dly. Titr.to achieve treatm.goal.   rot. oed., acne, photosens., incr.creatine phosphokinase, tendinous
   anticoags.incr., bioavailabil.decr.with cholestyramine theref. admin.   Safety & effic. of dos.&gt; 20 mg not stud.  contracture, bursit., gout, hyperton., leg cramps, myasthen., myosit.,
   1 hr.bef./4 hrs.aft.simvastatin admin.  Concom.ther: Addit.effic.shown.with concom. fenofibrate in low.  neck rigidity, tenosynovit., hyperkines., immune-mediat.necrotis.
                                triglycerid.& with niacin in incr. HDL-C lev. Can be used with bile acid   myopathy, arthrit., albuminur., cystit., dysur,, haematur., kidney cal-
   CRESAGEN, (Accord) Trinity [P/S]  sequestrant. & ezetimibe. With concom.gemfibrozil init.ther. with 5   culus, nephrit., noctur., urin.incontin./-retent./-urgency, impot., breast
   Rosuvastatin.                mg once dly.& do not exceed 20 mg once dly.  enlargem., epididymit., fibrocyst.breasts, metrorrhag., peripher.oed.,
   Indications: Prim.hypercholesterolaem./mix. dyslipidaem./isolat.hy-  Contraindications: Act.liv.dis., concom. ciclospor., myopathy, safety   malaise, fev., taste loss, taste pervers., tendon rupture, accident.inj.
   pertriglyceridaem. (incl. Fredrickson Type IIa, IIb & IV and heterozyg.   in pregn.& lactat.not est.  Warnings and special precautions: Excl. second. caus.prior to
   familial hypercholesterolaem.) when respons.to diet & exerc.inadeq.,   Side effects: Headache, dizzin., GI disturbs., pancreatit., myalgia,   init.ther.& meas.lipid profile., use in addit.to diet restrict.in saturat.fat
   homozygous familial hypercholesterolaem. either alone or as adjunct.  myopathy incl.myosit., rhabdomyolys. occas.report.with ren.impairm.,   & cholesterol only when response to diet & other non-pharmacolog.
   to diet & other lipid low.treatm.  asthen., rash, prurit., urticar., hypersens.reacts. incl. angio-oed., jaund.,   meas.inadeq., to be component of multipl-risk-fact.intervent.where
   (S4) TABS. 44/7.5/1065,1066,1067,1068  hepatit., incr.liv. transaminas. & CK, arthralg., memory loss.  risk of atherosclerot. vasc.dis.incr., 1 mnth.interv.betw. discont. ther.&
   723097-001: 5 mg, 30, R90,60  Special precautions: Consid.40 mg admin.only und. specialist   concept.in event of plann.pregn., LFT bef.init.ther./aft.each dos.incr./
   723098-001: 10 mg, 30, R141,30  supervis.in sev. hypercholesterolaem. & high CV risk when treatm.   period. thereaft., incr.transaminas.lev.should be monit. unt. stable,
   723099-001: 20 mg, 30, R217,50  goal not achiev.on 20 mg treatm./alternat.ther., monit. concom.war-  withdr.ther.if ALT/AST incr.&gt; 3x ULN persist, substant.alcoh.consum.,
   723100-001: 40 mg, 30, R259,20  far., HIV infect.pts.receiv. protease inhibit.in combinat.with ritonavir,   liv.dis.hist., discont. if CPK lev.are marked.elev.or if myopathy is diagn./
   Dosage: Init.& contin.cholest.low.diet bef.& dur. treatm. Dos.range   women of childbear.potent.to use adeq.contracept., exper. limit. to   susp., report unexpl.musc.pain/tender./ weakn. esp. if accomp.by fev./
   5-40 mg once dly. Recomm. start.dos: 5 mg once dly. Indiv.accord.  small numb.of childr.8 yrs & old.with homozygous familial hypercho-  malaise, withdr.in risk fact. predispos.to ren.fail.developm.second.to
   to ther.goal & pt.respons. Maj.pts.control.on 10 mg dos. Dos. adjustm.  lesterolaem., dos. above 10 mg once dly in sev.hepat./ren.impairm.,   rhabdomyolys/ with ac.serious condit.indicat. myopathy, monit.con-
   poss.at 2-4 wk interv.if necess.  consid. 5 mg start.dos in Asian pts.as plasma conc. incr., consid.incr.  com.digoxin/warfarin/ ezetemibe, monit.ren.& skelet.musc.funct.,
   Prim.hypercholesterolaem./mix.dyslipidaem. & isol.hyper-  system.expos.in Asian pts.not adeq. control.at dos.up to 20 mg dly.,   haemorrh. stroke/lacunar infarct hist., discont.ther. if interstit.lung dis.
   triglyceridaem: Recomm.start.dos: 5 mg once dly. also for pts.  adverse drug reacts. incr.with incr.dos., CK elev.& musc.sympts. fol-  susp, monit.pts.at high risk of future diab.mellit., concom.fusid.acid
   of Asian ancestry. Start. dos.of 20 mg may be consid.in sev. hy-  low. exerc./incr.activ.which resolv.with cont. treatm.observ.more freq.  not recomm., may affect glycaemic control in pts with diabet. mellit.
   percholesterolaem.           in childr.& adolesc., excess. alcoh.ingest., liv.dis.hist., monit.ren.funct.   Interactions: Myopathy risk incr.with concom. immunosuppress.
   Homozygous familial hypercholesterolaem: Start.recomm.  in pts. treat.with 40 mg, monit.CPK lev.if S&S suggest. of myopathy   agents incl.cyclospor./fibric acid derivat./ nicotin.acid/boceprevir/
   dos: 20 mg once dly.         pres.& discont.ther if myopathy is diagn./susp., incr.myosit.& myo-  ezetimibe/ telaprevir/ tipranavir+ritonavir/azole antifung.or eryth-
   Concom.ther: Addit.effic.shown.with concom. fenofibrate in lower.  pathy incid. report.in pts.receiv.high.dos.& other HMG-CoA reduct.  romycin & cytochrome P450 inhibits., poss. incr. plasma conc.with
   triglycerid.& may incr. HDL-C lev. with niacin. Bile acid sequestrant.   inhibit.tog.with ciclospor./fibric acid derivat. incl.gemfibrozil/nicotin.  protease inhibits./ erythromycin, incr.plasma lev.& rhabdomyolys.risk
   or ezetimibe can be used. Max.dos.10 mg/ day when used with pro-  acid/azole antifung. & macrolide antibiot., predispos. myopathy fact.  with cytochrome P4503A4 inhibit., incr.AUC with diltiazem HCl, poss.
   tease inhibits. Init. ther.with 5 mg once dly.& do not exceed 20 mg   eg. ren.impairm./advanc.age/ hypothyroid./ situat.where incr.plasma   reduc.plasma conc.with cytochrome P450 3A4 induc., Mg & Al oral
   once dly with concom. gemfibrozil.  lev.poss., withdr. in ac.ser.condit.suggest.of myopathy/ pre-dispos. to   antacids decr.plasma conc., colestipol  decr. plasma conc.although
   Contraindications: Other HMG-CoA reduct. inhibit.hypersens.,   ren.fail.developm.second.to rhabdomyolys, paed.height/BMI & sec-  LDLC reduct.was great.in combin. than when either med was giv.
   act.liv.dis., concom.cyclospor., myopathy, safety & effic.in childr.not   ond.sex. maturat. eval.limit.to 1 yr., lact.intol.  alone, digox. steady-state plasma conc. incr., poss.incr. plasma conc.
   demonstrat., safety in pregn.& lactat.not est.  Drug interactions: Steady state AUC (0-t) incr. with concom.ciclo-  with prod.from/juice of grapefruit, AUC values of norethindrone &
   Side effects: Myalg., myopathy, rhabdomyolys., hypersens.incl.an-  sporin., Cmax & AUC (O-t) incr. with gemfibrozil, incr.system.expos.  ethinyl estradiol incr.
   gioed., incr.ser.gluc.lev., headache, dizzin., CNS effs., cognit.impairm.,   with var. protease inhibit.in combinat.with ritonavir, oral antacids
   GI disturbs., abdom.pain, pancreatit., jaund., hepatit., incr.hepat.  contain Mg & Al decr. plasma conc.  INEGY, MSD (Pty) Ltd
   transamin., skin reacts., arthralg., proteinur., asthen.   See Section 7.7.4
   Warnings and special precautions: Consid. 40 mg ther.only in   DYNATOR, Pharma Dynamics [P/S]
   sev.hypercholesterolaem.& high CV risk who do not achieve treatm.  Atorvastatin.  LESCOL, Novartis [P/S]
   goal on 20 mg treatm./ alt.ther., post market.rhabdomyolys.rate high.  Indications: Adjunct.to diet for reduc.of elev.tot.-cholesterol, LDL-  Fluvastatin.
   at high.dos., meas.CK lev./discont.ther.if myopathy diagn./suspect.,   cholestrol, apolipoprot.-B & triglyceride lev.in prim.hypercholesterol-  Indications: Adults: Adjunct.to diet for reduct.of elev.tot.-C, LDL-
   incr.myosit.& myopathy incid. report.in pts.on other HMG-CoA reduct.   aem./mix. dyslipidaem., heterozygous familial hypercholesterolaem.,   C, apo B & TG lev.& incr.of HDL-C in prim. hypercholesterolaem.&
   inhibit. tog.with ciclospor./fibr.acid derivats.incl. gemfibrozil/ nicotin.  reduc.tot.-C & LDL-C in homozygous familial hypercholesterolaem.as   mix.dyslipidaem., slow.of coron.atheroscleros.progress.in prim. hy-
   acid/azole antifung.& macrolide antibiot., predispos.myopathy fact.  adjunt. to other lipid low. treatm.or if such treatm. unavail., in paed.   percholesterolaem. & concom.coron.heart dis. pts. who do not re-
   such ren. impairm./ hypothyroid./heredit.musc.disord. hist./ musc.  pts. 10-17 yrs.as adjunct.to diet reduc. total-C, LDL-C & apo B lev.in   spond.adeq.to diet.contr., reduc. risk coron.revascularisat.proced.
   toxic.hist.with anoth.statin/fibrate/ alcoh. abuse/age&gt;70 yrs.& con-  boys/ postmenarch. girls with heterozyg.famil. hypercholesterolaem.   in pts.with multivess. dis.
   com.fibrat./situat. where plasma lev.incr.may occur, condit.suggest.   if aft.adeq.diet ther.trial foll. pres: LDL-C remain.≥ 4,98 mmol/L (190   Childr.& adolesc.9 yrs.&old: Diet.adjunct to reduc. elev.total-C, LDL-
   of myopathy/ pre-dispos.to ren.fail.developm. second. to rhabdomy-  mg/dL) or LDL-C remain.≥ 4,04 mmol/L (160 mg/dL) and posit. fam.  C and apo B in heterozyg. famil. hypercholesterolaem.
   olys., concom.protease inhibit. in HIV, LFT prior to init.& as clinic.indict.   hist.of prem.CV dis./2 or more other CVD risk fact.pres, CV complic.  (S4) XL TABS, 35/7.5/0327
   thereaft., interrupt.ther if ser.liv.injury with clinic. sympts. and/or hyper-  prevent.where no clinic. evid.of CV dis.& with/-out dyslipidaem.but   700963-002: 80 mg, 28, R320,05
   bilirubinaem/jaund.occur, reg. assess ren.funct.with 40 mg dos., Type   with multipl.CHD risk fact., second.prevent.of CV events prev.in pts.  Dosage: Admin.in the even. & swallow whole. Init.& contin.choles-
   2 diab., concom. agents decr.activ.lev.of ster.horm.such as ketoconaz./   with clinic.evid.CHD & incr. cholestr.lev.  terol-low.diet ther.bef.& dur. treatm.
   spironolact./cimetid., reports of cognit. impairm., incr.expos.in Asian   (S4) TABS, A43/7.5/0167, 0168, 0169, 0170  Adults: Indiv. Start.dos: 40-80 mg once dly. Mild cases: 20 mg poss.
   pts., var.protease inhibit. with concom.ritonavir, lact.intol., monit.INR   718218-001: 10 mg, 30, R33,00  adeq. Max.eff.with giv.dos.is achiev.within 4 wks. Dos.adjustm.ac-
   with warfar., cons. benef./risk with concom. fenofibrat, women of child-  718219-001: 20 mg, 30, R34,80  cord.to respons. at interv.of 4 wks or more. Addit.eff. when combin.
   bear.potent.to use adeq. contracept., sev.ren./hepat.funct impairm.,  718220-001: 40 mg, 30, R61,20  with bile acid sequestrants., Therapeut. eff.maint.with prolong.admin.
   Drug interactions: Poss.INR incr.with concom. warfarin, AUC upto   718221-001: 80 mg, 30, R122,70  Paed: Start std.cholester.-low.diet 6 mnths prior to init.ther.& cont.
   7xhigh.with concom. ciclosporin, C max & AUC 2x incr.with gemfibrozil,   Dosage: Init.& contin.diet ther.bef.& dur.treatm. Init.10 mg once dly.   dur.treatm. Indiv. Start.dos: 40-80 mg once dly. Mild cases: 20 mg
   incr.system.expos.& adverse effs.with var. protease inhibit.in com-  Dos.indiv.accord.to baseline LDL-C lev.& pt.respons. Adjust dos.only   poss.adeq.
   binat.with ritonavir, antacids contain Mg & Al decr.plasma conc.,   aft.4 wks. or more. Max.recomm.dos.depend.on indicat.  Contraindications: Pregn., lactat., women of childbear.potent.not
   enhanc. skelet.musc. eff.with niacin, decr.AUC (o-t) & C max with   Prim.non-famil.hypercholesterolaem.& combin. (mix.) hyper-  tak.adeq.contracept., act.liv. dis., persist.unexpl.elev.serum transami-
   erythromycin, incr.ethinyl oestrad.& norgestrel AUC with oral con-  lipidaem: 10 mg once dly. Therap.response within 2 wks.& max.  nas., no data avail.in homozygous famil. hypercholesterolaem., sev.
   tracept.& simil.eff. with HRT cannot be excl., rhabdomyolys.report.   respons usual.within 4 wks.  ren.impairm., safety & effic. not stud.in pts.&lt;18 yrs.for treatm.per.long.
   with concom.ezetimibe,       Heterozygous familial hypercholesterolaem: Adults: Init.10 mg   than 2 yrs., only investigat.in childr.9 yrs.& old. with heterozyg.famil.
                                                              hypercholesterolaem., concom. HMG-CoA reduct.inhibits./fibrates.
                                once dly. Dos.indiv.& adjust. every 4 wks. up to 40 mg dly. Paed.pts.
   CRESTOR, AstraZeneca [P/S]   (&gt; 10-17 yrs): Init.10 mg/day with max.recomm.dos.20 mg/ day.  Side effects: GI disturbs., insomn., headache, thrombocytopen.,
   Rosuvastatin.                Homozygous familial hypercholesterolaem: Adults: Most re-  anaphylact.reacts., paraesthes., dysaesthes., hypoaesthes., vascu-
   Indications: CV event risk reduct.in adult pts.with incr.risk of ath-  spond to 80 mg.Limit.exper.in childr.  lit., pancreatit., hepatit., hypersens.& other skin reacts., myalg., musc.
   erosclerot.CV dis.bas.on CV dis.risk mark.to reduc.risk of non-fatal   CV complic.prevent: Dos.range: 10-20 mg once dly.  weakn., myopathy, rhabdomyolysis, myosit., lupus erythematos.-like
   stroke/non-fatal MI & need for arter.revascularisat., prim. hyper-  Contraindications: Act.liv.dis./persist.unexpl. elev.ser.transaminas.  reacts., potent.drug accumulat. in hepat.insuffic., abnorm.LFT with
   cholesterolaem./ mix.dyslipidaem./isolat. hypertriglyceridaem. incl.  conc., pregn.& lactat., women of childbear.potent.unless contracept.   elev. transamin.lev.3xULN
   Fredrickson Type IIa/IIb/& IV & heterozygous familial-& non-familial   adeq., safety & effic.not est.in childr., Child-Pugh B & C (liv.cirrhosis),   Special precautions: Poss.foet.harm if giv.dur. pregn., discont.if a
   hypercholesterolaem. as adjunct.to diet & exerc. when respons.in-  concom.rifampicin/diltiazem & grapefruit juice, herdit.probl./hist.  woman becom.pregn., monit. liv. funct.bef.& dur.treatm., liv.dis.hist.,
   adeq., prim. dysbetalipoproteinaem (Fredrickson Type III), reduc. tot.  of galact./ fruct.intol., Lapp lact. defic./gluc.-galact. malabsorpt./   heavy alcoh. ingest., discont.if CK lev.are marked.elev.or if myopathy is
   cholester.& LDL-C in homozygous familial hypercholesterolaem.alone   sucrase-isomalt insuffic., porphyria  diagn./suspect., in pre-dispos. rhabdomyolys. fact.& complicat.meas.
   or as adjunct. to diet & other lipid low.treatm.  Side effects: Freq: Infect., nasopharyngit., insomn., headache, si-  CK lev.bef. init. ther., withhold tempor.in ac./ser.condit. predispos. to
   Childr.10-17 yrs: Tot.cholester./LDL-C & APO B reduct.in heterozy-  nusit., pharyngolaryng. pain, epistax., LFT abnormal. Less freq: Al-  ren.fail.developm.second.to rhabdomyolysis, concom.immunosuppr.
   gous familial hypercholesterolaem.  lerg.reacts., pancreatit., hyperglycaem., hypoglycaem., weight gain,   agents/ cyclosporin/ gemifibrozil/nicotin.acid & erythromycin incr.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page160.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page156.html">156</a>&nbsp;&nbsp;&nbsp;<a href="page157.html">157</a>&nbsp;&nbsp;&nbsp;<a href="page158.html">158</a>&nbsp;&nbsp;&nbsp;<a href="page159.html">159</a>&nbsp;&nbsp;&nbsp;<a href="page160.html">160</a>&nbsp;&nbsp;&nbsp;<a href="page161.html">161</a>&nbsp;&nbsp;&nbsp;<a href="page162.html">162</a>&nbsp;&nbsp;&nbsp;<a href="page163.html">163</a>&nbsp;&nbsp;&nbsp;<a href="page164.html">164</a>&nbsp;&nbsp;&nbsp;<a href="page165.html">165</a>&nbsp;&nbsp;&nbsp;<a href="page166.html">166</a>
             </td>
             <td width="35%"><a href="page162.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page162.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
